A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Abemaciclib (Primary) ; Temuterkib (Primary)
- Indications Advanced breast cancer; Cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer; Urogenital cancer
- Focus Therapeutic Use
- 26 Jan 2024 Status changed from recruiting to discontinued. (Lack of efficacy. )
- 06 Jun 2023 Results (n=12) assessing the clinical efficacy of LY3214996 in combination with abemaciclib, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jan 2023 Planned End Date changed from 1 Sep 2023 to 1 Jul 2024.